Drug intelligence / Profile preview

ADC-Solid tumors (Fulgent)

Development stage: Preclinical
Lead developer: Fulgent Pharma
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

Fulgent Pharma's ADC-Solid tumors is a preclinical-stage antibody-drug conjugate (ADC) candidate being developed for the treatment of various solid malignancies. The program utilizes a proprietary linker and cytotoxic payload platform designed to enhance tumor reduction across different tumor types, regardless of the level of target antigen expression. While the specific target antigen, antibody, and payload have not been publicly disclosed, the company is focusing development on a broad range of cancers, including breast, lung, ovarian, colon, head and neck, and pancreatic cancers.

Other names: Fulgent Pharma ADC program

Beyond the preview

Go deeper on ADC-Solid tumors (Fulgent).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADC-Solid tumors (Fulgent).

Explore the full profile